With increasing information overload and packed work schedules, staying up-to-date on the newest oncologic advances is harder than ever. But take heart! The QuadShot is freshly brewed in your inbox four mornings each week so you can quickly down and digest the day's most pertinent cancer news.
As in, liquid biopsies. Circulating tumor DNA has been the subject of biomedical lunchroom conversation for years. But it was trending in a major way at ASCO this weekend and is now garnering interest from billionaire investors. Early reports indicate this blood test can be used to effectively screen and risk-stratify notoriously ambiguous presenters of lung, pancreatic and prostate cancers. Results are promising, but both oncologists and investors alike are wise to remember: all that glitters isn't liquid gold.